Plasma mSEPT9: A Novel Circulating Cell-free DNA-Based Epigenetic Biomarker to Diagnose Hepatocellular Carcinoma.
Fiche publication
Date publication
avril 2018
Journal
EBioMedicine
Auteurs
Membres identifiés du Cancéropôle Est :
Pr AYAV Ahmet, Pr BRONOWICKI Jean-Pierre, Pr GUEANT Jean-Louis, Dr NAMOUR Bernard, Dr OUSSALAH Abderrahim
Tous les auteurs :
Oussalah A, Rischer S, Bensenane M, Conroy G, Filhine-Tresarrieu P, Debard R, Forest-Tramoy D, Josse T, Reinicke D, Garcia M, Luc A, Baumann C, Ayav A, Laurent V, Hollenbach M, Ripoll C, Guéant-Rodriguez RM, Namour F, Zipprich A, Fleischhacker M, Bronowicki JP, Guéant JL
Lien Pubmed
Résumé
Patients with cirrhosis are at high risk of hepatocellular carcinoma (HCC). The SEPT9 gene is a key regulator of cell division and tumor suppressor whose hypermethylation is associated with liver carcinogenesis. The primary aim of this study was to evaluate the diagnostic accuracy of a PCR-based assay for the analysis of SEPT9 promoter methylation in circulating cell-free DNA (mSEPT9) for diagnosing HCC among cirrhotic patients.
Mots clés
Circulating cell-free DNA-based epigenetic biomarker, Cirrhosis, DNA methylation, Hepatocellular carcinoma, mSEPT9
Référence
EBioMedicine. 2018 Apr;30:138-147